Diligence memo · auto-generated · as of July 2, 2026
Tetralogic Pharmaceuticals Corp
Tetralogic Pharmaceuticals Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Tetralogic Pharmaceuticals Corp operates in Pharmaceuticals, based in MALVERN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tetralogic Pharmaceuticals Corp has raised $28M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2010-07-26.
Most recent recorded round closed around 2012-11-29.
Valuation (modeled)modeled
Provath models Tetralogic Pharmaceuticals Corp at approximately $155M (range $5.7M–$842M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.86× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 13.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 72% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 64% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.